New Technologies for the Glycosciences (R43/R44) | Apply Online

FAQs: New Technologies for the Glycosciences (R43/R44) - PA-16-157

What is the "New Technologies for the Glycosciences (R43/R44)" funding opportunity?

It is a discretionary NIH funding opportunity that uses the SBIR program to support small businesses developing practical, lower-cost tools and technologies that advance carbohydrate and glycan research (glycosciences). The Funding Opportunity Number is PA-16-157 and the activity codes are R43/R44.

Which grant mechanism and activity codes does this program use?

This opportunity uses the SBIR mechanism and is offered under the NIH R43/R44 activity codes. These codes generally reflect a phased approach to technology development, moving from early feasibility work toward more advanced development and potential commercialization.

Who is eligible to apply?

Eligible applicants are small businesses, consistent with SBIR requirements.

What is the main goal of the program?

The program aims to make glycoscience more accessible by funding technologies that remove persistent technical bottlenecks in how carbohydrates and glycans are made, measured, and interpreted. A recurring theme is improving affordability, standardization, usability, and robustness so typical biomedical labs can adopt the tools more easily.

What scientific areas are within scope?

The scope covers technology development across three broad areas: glycan synthesis, analytical reagents/technologies for glycoconjugate research, and informatics tools for glycan data analysis. The unifying objective is to make glycan and glycoconjugate research easier to perform, easier to reproduce, and easier to scale.

What kinds of glycan synthesis projects fit this opportunity?

Projects focused on new approaches for glycan synthesis are a major emphasis. Relevant concepts include methods that produce glycans or glycan-containing structures more efficiently, reproducibly, and affordably than traditional approaches, particularly where glycans are structurally complex and difficult to assemble.

What improvements in glycan synthesis does NIH seem to be looking for?

The opportunity highlights innovations that simplify synthesis workflows, increase yield, improve purity, enable automation, and/or broaden the range of glycan structures that can be made and accessed by researchers.

What are glycoconjugates, and why are they mentioned?

Glycoconjugates are biomolecules where carbohydrates are attached to proteins or lipids. Examples listed include glycoproteins, glycolipids, and proteoglycans. The opportunity is interested in tools and reagents that make it easier to study these kinds of molecules and their glycosylation patterns.

What types of analytical technologies are in scope?

In-scope analytical work can include improved reagents, assays, platforms, or instrumentation that make it easier to detect, quantify, characterize, or compare glycan structures and glycosylation patterns in glycoconjugates.

What does "easily accessible" mean in the context of this opportunity?

"Easily accessible" points to solutions that lower barriers for typical biomedical labs. The description emphasizes tools that are simpler to use, more standardized, less expensive, and more robust across settings, as opposed to highly specialized approaches that only a small number of expert labs can implement.

Are software and computational tools eligible under this announcement?

Yes. Informatics tools for glycan data analysis are explicitly called out as a key priority area under this opportunity.

What kinds of glycoinformatics capabilities fit the program priorities?

Examples described include software and computational approaches that improve glycan identification, annotation, standardization, visualization, integration with other omics datasets, database interoperability, and automated interpretation of analytical results. Tools supporting harmonized data formats and reproducible analysis are also described as especially relevant.

Why is glycan data analysis considered challenging?

The opportunity notes that glycan data can be difficult to interpret because of structural diversity, branching, and inconsistent ways glycans are represented across databases and analytical outputs. These factors have historically made comparisons across studies challenging.

How does this SBIR opportunity relate to the NIH Common Fund glycoscience initiative?

This program is described as complementary to the NIH Common Fund initiative "Accelerating Translation of Glycoscience Integration and Accessibility" (launched in 2015). A key distinction noted is that Common Fund programs do not use SBIR mechanisms, while this opportunity explicitly does, focusing on small-business-led innovation with a pathway toward product development and broad dissemination.

What is the intended downstream impact of funded projects?

The opportunity is positioned as an NIH-backed push to expand the practical toolkit of glycoscience by enabling small companies to turn difficult carbohydrate research tasks into affordable, standardized, and user-friendly products that can be widely adopted.

When was this funding opportunity posted, and when did it close?

The opportunity was created and posted on March 30, 2016. The original and current closing date listed is April 5, 2019.

Is the award ceiling or number of awards provided in the information shown?

No. The provided information indicates that an award ceiling and the expected number of awards are not specified in the listed fields. It suggests applicants would need to refer to NIH SBIR budget guidelines, institute participation, and the full funding announcement for details such as budget caps, project periods, and submission cycles (as applicable when the announcement was active).

Which broader federal program identifiers are associated with this opportunity?

The opportunity sits within the NIH and HHS health research landscape and references CFDA numbers 93.121, 93.859, and 93.867.

What kinds of projects appear to be a strong fit overall?

Based on the description, strong-fit projects are those that reduce cost and complexity in glycoscience workflows and result in tools that are practical for broad use. This includes advances in wet-lab synthesis, measurement and characterization technologies, and software that improves interpretation, standardization, and interoperability of glycan data.